Science
Unlocking Breakthrough Orally Delivered Enzyme Therapeutics
Malabsorption syndromes and nutrient metabolism disorders are conditions that prevent the body from properly metabolizing or absorbing sugars, fats, proteins, vitamins or other key nutrients. This leads to devastating consequences, impacts how people live their lives, and often can be life-threatening.
At Anagram we are using the power of orally delivered enzyme therapeutics to address significant unmet needs in malabsorption syndromes and nutrient metabolism disorders, focusing on diseases where we believe we have a high probability of technical success.
- Enzymes are ideal therapeutics since they bind to specific substrates (e.g., lipase > fats) to exert a therapeutic effect.
- As large molecules, orally delivered enzymes are not absorbed and function in the gastrointestinal tract providing significant safety advantage.
Our experience and the novel technologies we use enable us to address the historic challenge of the gastric environment being too harsh for orally delivered enzymes to survive and be therapeutically effective.
We use decades of experience to understand gastrointestinal physiology for each disease we target, and align sensitive testing tools to precisely produce novel targeted orally delivered enzymes. We partner with the best scientific minds and collaborators from around the world to deliver better treatment options.
Our Science at Work
At Anagram Therapeutics, our 20+ years of domain expertise informs the development of orally delivered enzymes. Here’s a snapshot of how we work.
